Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994081 · ClinicalTrials.gov registry record · NA
Mechanism of Action of tACS for the Treatment of MDD
A NA study of Major Depressive Disorder and MDD, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03994081: Completed NA study of Major Depressive Disorder and MDD, sponsored by University of North Carolina, Chapel Hill.
NCT03994081 is a NA study of Major Depressive Disorder and MDD that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 20 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03994081, a NA study of Major Depressive Disorder and MDD, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to use a specific type of non-invasive brain stimulation known as transcranial alternating current stimulation (tACS) to determine its effects on brain activity (measured with EEG) and mood in patients with Major Depressive Disorder (MDD).
Primary Outcome
Fourier transform is applied to 2 second epochs of resting-state EEG data and averaged across epochs. The amplitude of alpha oscillations is calculated and averaged across left frontal electrodes. The difference between the baseline recording on the first day of stimulation is compared to the recording on the fifth day of the intervention prior to stimulation.
Conditions Studied
Interventions
- DEVICE tACS
- DEVICE Sham tACS
Study Locations (1)
North Carolina
- UNC at Vilcom Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2023-06-02 |
| Phase | NA |
What the finished NCT03994081 record still lists
NCT03994081 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which tACS is the first listed.
NCT03994081 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03994081 about?
NCT03994081 is a clinical study titled "Mechanism of Action of tACS for the Treatment of MDD". The purpose of this research study is to use a specific type of non-invasive brain stimulation known as transcranial alternating current stimulation (tACS) to determine its effects on brain activity (measured with EEG) and mood in patients with Major Depressive Disorder (MDD).
What is the current status of trial NCT03994081?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2021-06-09. Estimated completion is 2023-06-02.
What conditions does trial NCT03994081 study?
This clinical trial studies the following conditions: Major Depressive Disorder, MDD.
What interventions are being tested in trial NCT03994081?
The interventions under investigation include: tACS (DEVICE), Sham tACS (DEVICE).
Who is sponsoring clinical trial NCT03994081?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03994081 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03994081's enrollment target sits among peer trials
20 243rd of 282 higher than 34 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI